NCT06385080

Phase 1/Phase 2Interventional

Trials that are a combination of phases 1 and 2.

View on ClinicalTrials.gov ↗

Timeline

Start date: Apr 22, 2024
Primary completion: Jul 17, 2026
Completion date: Apr 15, 2027
First posted: Apr 25, 2024
Last posted: Oct 10, 2024
Enrollment: 117
Arms / groups: 4 / —
Source: AACT · ctgov ingestion

Drugs studied

paclitaxel
pembrolizumab
amivantamab-vmjw

Indications studied

Squamous Cell Carcinoma of Head and Neck

CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.